Beijing Kawin Technology Share-Holding Co., Ltd. Stock

Equities

688687

CNE1000054C3

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
29.94 CNY +2.11% Intraday chart for Beijing Kawin Technology Share-Holding Co., Ltd. +1.80% -14.11%

Financials

Sales 2024 * 1.71B 236M 323M Sales 2025 * 2.2B 303M 415M Capitalization 5.01B 692M 948M
Net income 2024 * 148M 20.44M 27.98M Net income 2025 * 198M 27.35M 37.43M EV / Sales 2024 * 2.93 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 2.28 x
P/E ratio 2024 *
34.7 x
P/E ratio 2025 *
25.9 x
Employees 584
Yield 2024 *
1.05%
Yield 2025 *
1.5%
Free-Float 69.27%
More Fundamentals * Assessed data
Dynamic Chart
China stocks down pressured by real estate; HK shares up RE
Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Beijing Kawin Technology Share-Holding Plans Share Private Placement to Fund Project, Replenish Capital CI
Beijing Kawin Technology Share-Holding Co., Ltd. announced that it expects to receive CNY 300 million in funding CI
Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kawin Technology Gets Nod to Carry Out Trials Into Tumor Drug MT
Beijing Kawin Technology Share-Holding Co., Ltd.'s Equity Buyback announced on June 1, 2022, has expired. CI
Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beijing Kawin Technology Share-Holding Co., Ltd. announced that it expects to receive CNY 300 million in funding CI
Tranche Update on Beijing Kawin Technology Share-Holding Co., Ltd.'s Equity Buyback Plan announced on June 1, 2022. CI
Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Beijing Kawin Technology Share-Holding Co., Ltd.'s Equity Buyback Plan announced on June 1, 2022. CI
More news
1 day+2.11%
1 week+1.80%
1 month-6.70%
3 months+39.71%
6 months-1.58%
Current year-14.11%
More quotes
1 week
29.10
Extreme 29.1
30.88
1 month
23.63
Extreme 23.63
33.39
Current year
18.50
Extreme 18.5
35.79
1 year
18.50
Extreme 18.5
37.63
3 years
14.76
Extreme 14.76
38.13
5 years
14.76
Extreme 14.76
70.00
10 years
14.76
Extreme 14.76
70.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 08-07-31
Director of Finance/CFO 38 19-10-31
Director/Board Member 40 11-04-30
Members of the board TitleAgeSince
Director/Board Member 50 11-06-30
Director/Board Member 54 21-05-11
Director/Board Member 69 21-05-11
More insiders
Date Price Change Volume
24-04-30 29.94 +2.11% 3,504,297
24-04-29 29.32 -0.31% 5,325,721
24-04-26 29.41 +3.92% 4,753,095
24-04-25 28.3 +2.17% 5,601,082

End-of-day quote Shanghai S.E., April 29, 2024

More quotes
Beijing Kawin Technology Share-Holding Co Ltd is a China-based company principally engaged in the production and sales of therapeutic drugs in the viral disease field, and the research and development of innovative drugs. The Company's recombinant human interferon α2b and compound glycyrrhizin drugs are applied to treat viral diseases. The Company mainly distributes its products within domestic market.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
29.94 CNY
Average target price
39.66 CNY
Spread / Average Target
+32.46%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688687 Stock